Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-03-30
2000-11-21
Davis, Zinna Northington
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514340, 514369, 514376, 5462697, 5462714, 548183, 548227, C07D40102, A61K 3144, A61K 31425, A61K 3142
Patent
active
061503835
ABSTRACT:
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
REFERENCES:
patent: 5859037 (1999-01-01), Whitcomb
M. Tominaga et al. "Thiazolidinediones (AD-4833 and CS-045) Improve Hepatic Insulin Resistance in Streptozotocin-Induced Diabetic Rats", Endocrine Journal, vol. 40, No. 3, pp. 345-349, 1993.
C. Hofmann et al., "Glucose Transport Deficiency in Diabetic Animals is Corrected by Treatment with the Oral Antihyperglycemic Agent Pioglitazone", Endocrinology, vol. 129, No. 4, pp. 1915-1925, 1991.
J. Karam, "Type II Diabetes Syndrome X", Endocrinology and Metabolism Clinics of North America, vol. 21, No. 2, pp. 329-350, 1992.
S. Suter et al., "Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects", Diabetes Care, vol. 15, No. 2, pp. 193-203, 1992.
T. Toyoda, Iyaku Journal, vol. 30, No. 4, pp. 1130-1134, 1994.
Y. Sugiyama et al., "Effects of Pioglitazone on Glucose and Lipid Metabolism in Wistar Fatty Rats", Arzneim.-Forsch/Drug Res., vol. 40, No. 1, pp. 263-267, 1990.
Ishida et al., "Oral Hypoglycemic Agents--New Oral Drugs and New Strategy of Treatment", Clinic All-round, vol. 43, pp. 2615-2621, 1994 (and English translation).
Therapeutic Research, 14 (No. 10), 4122 to 4126 (1993) (and English translation).
Clinic and Medicine, 9 (Suppl. 3), 19 to 37 (1993).
Clinic and Medicine, 9 (Suppl. 3), 39 to 60 (1993).
Recent Medicine, 33 197 (1982).
Sugiyama et al., "Effects of Pioglitazone on Hepatic and Peripheral Insulin Resistance in Wistar Fatty Rats," Arzneim.-Forsch., vol. 40, pp. 436-440 (Apr. 1990).
Ikeda et al., "Effects of Pioglitazone on Glucose and Lipid Metabolism in Normal and Insulin Resistant Animals," Arzneim.-Forsch., vol.40, pp. 156-162 (Feb. 1990).
Hofmann et al., "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers," Diabetes Care, vol. 15, pp. 1075-1078 (Aug. 1992).
Hofmann et al., "Treatment of Insulin-Resistant Mice with the Oral Antidiabetic Agent Pioglitazone: Evaluation of Liver GLUT2 and Phosphoenolpyruvate Carboxykinase Expression," Endocrinology, vol. 130, pp. 735-740 (Feb. 1992).
Iwashini, et al., "Effect of Proglitazone on Insulin Receptors of Skeletal Muscles from High Fat-Fed Rats," Metabolism, vol 42, pp. 1017-1021 (Aug. 1993).
Iwanishi et al., "New Oral Agent to Increase Insulin Sensitivity by Activating Kinase Activity of Insulin Receptors," Diabetes, vol. 39, abstract 474 (Jun. 1990).
Kobayashi et al., "Pioglitazone Increases Insulin Sensitivity by Activating Insulin Receptor Kinase," Diabetes, vol. 41, pp. 476-483 (Apr. 1992).
Hofmann et al., "Insulin Sensitization in Diabetic Rat Liver by an Antihyperglycemic Agent," Metabolism, vol. 44, pp. 384-389 (Mar. 1995).
de Souza et al., "Insulin Secretory Defect in Zucker fa/fa Rats is Improved by Ameliorating Insulin Resistance," Diabetes, vol. 44, pp. 984-991 (Aug. 1995).
Hofmann et al., "Glucose Transport Deficiency in Diabetic Animals in Corrected by Treatment with the Oral Antihyperglycemic Agent Pioglitazone," Endocrinology, vol. 129, pp. 1915-1925 (Mar. 1991).
Colca et al., "Antihyperglycaemic Thiazolidinediones: Ciglitazone and its Analogues," New Antidiabetic Drugs, pp. 255-261 (1990).
Tominaga et al., "Thiazolidinediones (AD-4833 and CS-045) Improve Hepatic Insulin Resistance in Streptozotocin-Induced Diabetic Rats," Endocrine Journal, vol. 40, pp. 343-349 (Jun. 1993).
Weinstock et al., "Pioglitazone: In Vitro Effects on Rat Hepatoma Cells and in vivo Liver Hypertrophy in KKA.sup..gamma. Mice," Pharmacology, vol. 54, pp. 169-178 (Apr. 1997).
El-Kebbi et al., "Regulation of Glucose Transport by Pioglitazone in BC3H-1 Myocytes," Clinical Resarch, vol. 39, p. 837A (Dec. 1991).
Kemnitz et al., "Pioglitazone Increases Insulin Sensitivity, Reduces Blood Glucose, Insulin, and Lipid Levels, and Lowers Blood Pressue in Obese, Insulin-Resistant Rhesus Monkeys," Diabetes, vol. 43, pp. 204-211 (Feb. 1994).
Meehan et al., "Pioglitazone Reduces Blood Pressure and Improves Insulin Sensitivity in Fructose-Fed Rats," Clinical Research, vol. 41, p. 21A (Feb. 1993).
Colca et al., "Pioglitazone Hydrochloride Inhibits Cholesterol Absorption and Lowers Plasma Cholesterol Concentrations in Cholesterol-Fed Rats," Diabetes, vol. 40, pp. 1669-1674 (Dec. 1991).
Sohda et al., "Studies on Antidabetic Agents, 11. Novel Thiazolidinedione Derivatives as Potent Hypoglycemic and Hypolipidemic Agents," Journal of Medicinal Chemistry, vol. 35, pp. 2617-2626 (Jul. 1992).
Sugiyama et al., "Pathogenesis Hyperglycemia in Genetically Obese-Hyperglycemic Rats, Wistar Fatty: Presence of Hepatic Insulin Resistance," Endocrinologia Japonica, vol. 36, pp. 65-73 (Feb. 1989).
Suter et al., "Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects," Diabetes Care, vol. 15, pp. 193-203 (Feb. 1992).
Iwamoto et al., "Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM," Diabetes Care, vol. 14, pp. 1083-1086 (Nov. 1991).
Norris et al., Comparison of Troglitazone (C1991) Dosing Regimens and Placebo in the Treatment of Patients with NIDDM, Diabetes, vol. 42, Supp. 1, Abstract 188 (Jun. 1993).
Fukuda et al., "Results of a Pilot Study in which Troglitazone and Insulin were Jointly Administered to NIDDM Patients," Journal of Clinical Therapeutics & Medicines, vol. 11, pp. 2055-2062 (Oct. 1995). (with translation, based on abstract published at 15th Diabetes Fed. Cong., Nov. 6-11, 1994, Kobe).
Kanazawa, "Agent for Lowering Insulin Resistance--CS-045," Diabetes Frontier, vol. 3, pp. 570-574 (1992).
Onuma et al., "The Effect of a New Oral Hypoglycemic Drug, CS-045, on Glucose Tolerance and Serum Lipids in Nonobese Japanese Patients with Non-Insulin-Dependent Diabetes Mellitus: A Pilot Study," Current Therapeutic Research, vol. 55, pp. 416-421 (Apr. 1994).
Kuzuya et al., "A Pilot Clinical Trial of a New Oral Hypoglycemic Agent, CS-045, in Patients with Non-Insulin Dependent Diabetes Mellitus," Diabetes Research and Clinical Practice, vol. 11, pp. 147-154 (1991).
Takino et al., "Increased Insulin Responsiveness After CS-045 Treatment of Diabetes Associated with Werner's Syndrome," Diabetes Research and Clinical Practice, vol. 24, pp. 167-172 (Jul. 1994).
Fujiwara et al., "Characterization of New Oral Antidiabetic Agent CS-045," Diabetes, vol. 37, pp. 1549-1558 (Sep. 1988).
Lee et al., "Metabolic Effects of Troglitazone on Fructose-Induced Insulin Resistance in the Rat," Diabetes, vol. 43, pp. 1435-1439 (Dec. 1994).
Khoursheed et al., "Metabolic Effects of Troglitazone on Fat-Induced Insulin Resistance in the Rat," Metabolism, vol. 44, pp. 1489-1494 (Nov. 1995).
Valiquett et al., "Troglitazone Dose-Response Study in Patients with Noninsulin Dependent Diabetes," Clinical Research, vol. 42, p. 400A (Oct. 1994).
Nolan et al., "Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone," The New England Journal of Medicine, vol. 331, pp. 1188-1193 (Nov. 1994).
Ciaraldi et al., "In Vitro Studies on the Action of CS-045, a New Antidiabetic Agent," Metabolism, vol. 39, pp. 1056-1062 (Oct. 1990).
Oakes et al., A New Antidiabetic Agent, BRL 49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the Rats, Diabetes, vol. 43, pp. 1203-1210 (Oct. 1994).
Eldershaw et al., "Treatment with the Thiazolidinedione (BRL 49653) Decreases Insulin Resistance in Obese Zucker Hindlimb," Hormone and Metabolic Research, vol. 27, pp. 169-172 (Apr. 1995).
Cawthorne et al., "Anti-Hyperglycaemic Efficacy of BRL-49653, a Highly Potent Thiazolidinedione, in Animal Models of Non-Insulin Dependent Diabetes," Diabetes, vol. 42, Supp. 1, Abstract 654 (Jun. 1993).
Kraegen et al., "Effects of BRL 49653 in Normal and Insulin Resistant (High-Fat-Fed) Rats; New Information on the Mode of Action of Thiazolidinediones," Diabetes, vol. 42, Supp. 1, Abstract 257 (Jun. 1993).
Smith et
Ikeda Hitoshi
Odaka Hiroyuki
Sohda Takashi
Davis Zinna Northington
Takeda Chemical Industries Ltd.
LandOfFree
Pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1257669